分组1 - MDxHealth SA reported a quarterly loss of $0.15 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.13, but an improvement from a loss of $0.31 per share a year ago, indicating a surprise of -15.38% [1] - The company posted revenues of $26.61 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.02% and showing an increase from $22.16 million in the same quarter last year [2] - MDxHealth SA shares have increased by approximately 4.2% since the beginning of the year, while the S&P 500 has gained 7.6%, indicating underperformance relative to the broader market [3] 分组2 - The earnings outlook for MDxHealth SA is uncertain, with current consensus EPS estimates of -$0.11 for the coming quarter and -$0.52 for the current fiscal year, alongside expected revenues of $27.8 million and $108.5 million respectively [7] - The Zacks Industry Rank places the Medical Info Systems sector in the top 29% of over 250 Zacks industries, suggesting that companies in the top half of the rankings tend to outperform those in the bottom half by more than 2 to 1 [8] - The estimate revisions trend for MDxHealth SA was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold), indicating that the stock is expected to perform in line with the market in the near future [6]

Group 1 - American Well Corporation (AMWL) reported a quarterly loss of $1.24 per share, which was better than the Zacks Consensus Estimate of a loss of $1.84, and an improvement from a loss of $3.36 per share a year ago, resulting in an earnings surprise of +32.61% [1] - The company posted revenues of $70.9 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 11.42%, and showing an increase from year-ago revenues of $62.79 million [2] - American Well has surpassed consensus EPS estimates four times over the last four quarters and has topped consensus revenue estimates three times during the same period [2] Group 2 - The stock has underperformed the market, losing about 2.9% since the beginning of the year, while the S&P 500 has gained 7.6% [3] - The current consensus EPS estimate for the upcoming quarter is -$1.98 on revenues of $63.11 million, and for the current fiscal year, it is -$6.91 on revenues of $255.84 million [7] - The Medical Info Systems industry, to which American Well belongs, is currently ranked in the top 29% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]

Group 1: Earnings Performance - Hackett Group reported quarterly earnings of $0.38 per share, matching the Zacks Consensus Estimate, but down from $0.39 per share a year ago [1] - The company posted revenues of $77.63 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 1.30% and up from $75.9 million year-over-year [2] - Over the last four quarters, Hackett Group has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2][3] Group 2: Stock Performance and Outlook - Hackett Group shares have declined approximately 24.2% since the beginning of the year, contrasting with the S&P 500's gain of 7.6% [3] - The company's earnings outlook is crucial for assessing future stock performance, with current consensus EPS estimates at $0.43 for the coming quarter and $1.64 for the current fiscal year [4][7] - The estimate revisions trend for Hackett Group was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Group 3: Industry Context - The Consulting Services industry, to which Hackett Group belongs, is currently ranked in the top 12% of over 250 Zacks industries, suggesting a favorable outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Company Performance - Kemper reported quarterly earnings of $1.3 per share, missing the Zacks Consensus Estimate of $1.52 per share, and down from $1.42 per share a year ago, representing an earnings surprise of -14.47% [1] - The company posted revenues of $1.23 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.34%, and up from $1.13 billion year-over-year [2] - Over the last four quarters, Kemper has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times [2] Stock Outlook - Kemper shares have lost about 8.3% since the beginning of the year, while the S&P 500 has gained 7.6% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is $1.57 on $1.26 billion in revenues, and for the current fiscal year, it is $6.34 on $4.98 billion in revenues [7] Industry Context - The Zacks Industry Rank for Insurance - Multi line is currently in the top 38% of over 250 Zacks industries, indicating a favorable outlook for the sector [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that tracking these revisions can be beneficial for investors [5][6]

Financial Performance - Evolus, Inc. reported a quarterly loss of $0.24 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.09, representing an earnings surprise of -166.67% [1] - The company posted revenues of $69.39 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 16.33%, compared to year-ago revenues of $66.91 million [2] - Over the last four quarters, Evolus has not surpassed consensus EPS or revenue estimates [2] Stock Performance - Evolus shares have declined approximately 17.5% since the beginning of the year, while the S&P 500 has gained 7.6% [3] - The current Zacks Rank for Evolus is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $86.76 million, and -$0.11 on revenues of $350.01 million for the current fiscal year [7] - The outlook for the Medical - Products industry, to which Evolus belongs, is currently in the bottom 38% of over 250 Zacks industries, which may impact the stock's performance [8]

Group 1: Earnings Performance - California Resources Corporation (CRC) reported quarterly earnings of $1.1 per share, exceeding the Zacks Consensus Estimate of $0.91 per share, and up from $0.6 per share a year ago, representing an earnings surprise of +20.88% [1] - The company posted revenues of $978 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 21.84%, compared to year-ago revenues of $514 million [2] - Over the last four quarters, California Resources has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times [2] Group 2: Stock Performance and Outlook - California Resources shares have declined approximately 9.1% since the beginning of the year, while the S&P 500 has gained 7.6% [3] - The current consensus EPS estimate for the coming quarter is $1.06 on revenues of $845.76 million, and for the current fiscal year, it is $3.71 on revenues of $3.32 billion [7] - The company's earnings outlook and estimate revisions will be crucial for future stock performance, with a current Zacks Rank of 3 (Hold), indicating expected performance in line with the market [6] Group 3: Industry Context - The Oil and Gas - Exploration and Production - United States industry is currently in the bottom 31% of over 250 Zacks industries, which may impact the stock's performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that tracking these revisions can be beneficial for investors [5]

Core Viewpoint - Gulfport Energy reported quarterly earnings of $4.24 per share, missing the Zacks Consensus Estimate of $5.03 per share, representing an earnings surprise of -15.71% [1] - The company posted revenues of $447.62 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 33.79% [2] Financial Performance - Earnings per share (EPS) for the same quarter last year was $2.91, indicating a year-over-year increase [1] - Gulfport has surpassed consensus EPS estimates three times over the last four quarters [2] - The company has topped consensus revenue estimates just once over the last four quarters [2] Stock Performance - Gulfport shares have declined approximately 9.4% since the beginning of the year, while the S&P 500 has gained 7.6% [3] - The current Zacks Rank for Gulfport is 3 (Hold), indicating expected performance in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $6.29, with expected revenues of $366.77 million [7] - For the current fiscal year, the consensus EPS estimate is $22.78 on revenues of $1.44 billion [7] - The outlook for the industry, specifically the Oil and Gas - Exploration and Production - United States sector, is currently in the bottom 31% of Zacks industries, which may impact Gulfport's stock performance [8]

Company Performance - Myriad Genetics reported quarterly earnings of $0.05 per share, exceeding the Zacks Consensus Estimate of a loss of $0.01 per share, representing an earnings surprise of +600.00% [1] - The company posted revenues of $213.1 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 5.55% and showing a slight increase from $211.5 million year-over-year [2] - Over the last four quarters, Myriad has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times as well [2] Stock Outlook - Myriad shares have declined approximately 71% since the beginning of the year, contrasting with the S&P 500's gain of 7.6% [3] - The current consensus EPS estimate for the upcoming quarter is $0.01 on revenues of $205.1 million, while for the current fiscal year, the estimate is -$0.01 on revenues of $811.68 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Myriad belongs, is currently ranked in the bottom 43% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Myriad's stock performance [5]

Core Viewpoint - Gossamer Bio reported a quarterly loss of $0.17 per share, slightly better than the Zacks Consensus Estimate of a loss of $0.18, marking an earnings surprise of +5.56% [1] - The company has consistently surpassed consensus EPS estimates over the last four quarters [2] Financial Performance - Gossamer Bio posted revenues of $11.49 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 155.88%, compared to revenues of $95.84 million a year ago [2] - The company has also topped consensus revenue estimates four times in the last four quarters [2] Stock Performance - Gossamer Bio shares have increased approximately 139.9% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.6% [3] Future Outlook - The company's earnings outlook will be crucial for investors, particularly in understanding how current consensus earnings expectations may evolve [4] - The current consensus EPS estimate for the upcoming quarter is -$0.18 on revenues of $5.78 million, and for the current fiscal year, it is -$0.69 on revenues of $28.57 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Gossamer Bio belongs, is currently ranked in the bottom 43% of over 250 Zacks industries, indicating potential challenges ahead [8]

Group 1 - Lucid Group reported a quarterly loss of $0.28 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.22, representing an earnings surprise of -27.27% [1] - The company posted revenues of $259.43 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 2.37%, and showing an increase from $200.58 million year-over-year [2] - Over the last four quarters, Lucid Group has surpassed consensus revenue estimates three times [2] Group 2 - The stock has underperformed, losing about 20.2% since the beginning of the year, while the S&P 500 has gained 7.6% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.26 on revenues of $375.43 million, and for the current fiscal year, it is -$0.89 on revenues of $1.31 billion [7] - The Zacks Industry Rank for Automotive - Domestic is currently in the bottom 29% of over 250 Zacks industries, indicating potential challenges for the sector [8]